Solid Biosciences Inc.

NasdaqGS:SLDB Stok Raporu

Piyasa değeri: US$640.9m

Solid Biosciences Yönetim

Yönetim kriter kontrolleri 2/4

Solid Biosciences CEO'su Bo Cumbo, Dec2022 tarihinde atandı, in görev süresi 3.42 yıldır. in toplam yıllık tazminatı $ 5.22M olup, şirket hissesi ve opsiyonları dahil olmak üzere 12.5% maaş ve 87.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.24% ine doğrudan sahiptir ve bu hisseler $ 1.53M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.4 yıl ve 8.3 yıldır.

Anahtar bilgiler

Bo Cumbo

İcra Kurulu Başkanı

US$5.2m

Toplam tazminat

CEO maaş yüzdesi12.46%
CEO görev süresi3.4yrs
CEO sahipliği0.2%
Yönetim ortalama görev süresi3.4yrs
Yönetim Kurulu ortalama görev süresi8.3yrs

Son yönetim güncellemeleri

Recent updates

Seeking Alpha • Mar 12

Solid Biosciences: Interim Data Lends Credibility For Q1 2026 Trial Start

Summary Solid Biosciences retains a "Strong Buy" rating, driven by robust interim data for SGT-003 in pediatric Duchenne Muscular Dystrophy [DMD]. The company demonstrated 60% mean microdystrophin expression at Day 90 in its phase 1/2 INSPIRE DUCHENNE trial, with safety confirmed in 40 patients. A $240 million private placement in March 2026 extends the cash runway, supporting key milestones through 2027. Upcoming catalysts include phase 3 IMPACT DUCHENNE first dosing in Q1 2026 and a potential FDA Accelerated Approval update by mid-2026. Read the full article on Seeking Alpha
Analiz Makalesi • Oct 23

We're Keeping An Eye On Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analiz Makalesi • Jul 09

We're Not Very Worried About Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Apr 08

Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space

Summary Solid Biosciences is repositioning itself in a scrutinized space with promising early-stage trial results for its lead candidate, SGT-003. Recent events involving Sarepta Therapeutics have unfairly impacted Solid's stock price, creating a potential recovery opportunity if Sarepta clarifies the isolated nature of the patient's death. Solid's pipeline includes SGT-003 for DMD, SGT-212 for Friedreich’s ataxia, and SGT-501 for CPVT, with promising early data and no serious adverse effects. Despite risks, Solid's strong financial position and potential market disruption with SGT-003 make it a Buy, assuming continued safety and favorable Sarepta developments. Read the full article on Seeking Alpha
Seeking Alpha • Jan 21

Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself Apart

Summary Initiation of phase 1b study, using gene therapy SGT-212 for the treatment of patients with Friedreich's Ataxia, expected 2nd half of 2025. The global Friedreich's Ataxia market is expected to grow to $7.56 billion in 2034. Data from the first 3 patients of the phase 1/2 INSPIRE DUCHENNE study, using SGT-003 for the treatment of patients with Duchenne Muscular Dystrophy, expected in Q1 of 2025. SGT-501 is another gene therapy product candidate with an expected IND filing in the 1st half of 2025 for the treatment of patients with RYR2-mediated Catecholaminergic Polymorphic Ventricular Tachycardia. Read the full article on Seeking Alpha
Analiz Makalesi • Nov 16

Is Solid Biosciences (NASDAQ:SLDB) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analiz Makalesi • Jul 26

We Think Solid Biosciences (NASDAQ:SLDB) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Solid...
Seeking Alpha • Apr 10

Buy Solid Biosciences: Unpacking Its Main Value Driver

Summary Solid Biosciences is focused on gene therapy innovation for neuromuscular and cardiac conditions. Their flagship drug therapy for Duchenne muscular dystrophy (DMD) is expected to be tested in Q2 2024. SLDB recently received additional liquidity from a PIPE investment, improving its risk-reward equation. SLDB's valuation appears undervalued relative to its peers, which is why I ultimately lean bullish post-PIPE investment. Read the full article on Seeking Alpha
Seeking Alpha • Jan 17

Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid

Summary IND SGT-003 gene therapy cleared for phase 1/2 testing: First patient dosing expected late Q1 2024 with biomarker/functional data expected Q3 of 2024. The global Duchenne Muscular Dystrophy drugs market is expected to reach $27.4 billion by 2030. Solid Biosciences might be able to overcome gene therapy competitors in the DMD space with its own proprietary capsid of AAV-SLB101, which may end up having better transgene expression. An IND filing to begin a phase 1 study using SGT-501 for the treatment of patients with catecholaminergic polymorphic ventricular tachycardia is expected by Q1 of 2025. Read the full article on Seeking Alpha
Seeking Alpha • Sep 30

Solid Biosciences to acquire gene therapy company AavantiBio

Life sciences company Solid Biosciences (NASDAQ:SLDB) will acquire the gene therapy company AavantiBio. The combined entity aims to advance a portfolio of neuromuscular and cardiac programs. The merger is subject to an approval by the shareholders of Solid. Post the transaction, the current CEO of AavantiBio, Bo Cumbo, will assume the role of president and CEO of Solid Biosciences. In support of the acquisition, SLDB has entered into a securities purchase agreement with a select group of institutional investors and accredited investors for a $75M private placement. The private placement is expected to close concurrently with the closing of the merger in Q4. The combined entity is expected to have total cash and investments of ~$215M post the closing of the merger. SLDB shares were trading +17.47% pre-market. Source: Press Release
Analiz Makalesi • Apr 30

Analysts Have Lowered Expectations For Solid Biosciences Inc. (NASDAQ:SLDB) After Its Latest Results

It's shaping up to be a tough period for Solid Biosciences Inc. ( NASDAQ:SLDB ), which a week ago released some...
Analiz Makalesi • Apr 28

Some Analysts Just Cut Their Solid Biosciences Inc. (NASDAQ:SLDB) Estimates

The latest analyst coverage could presage a bad day for Solid Biosciences Inc. ( NASDAQ:SLDB ), with the analysts...
Analiz Makalesi • Mar 17

We're Keeping An Eye On Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

CEO Tazminat Analizi

Bo Cumbo'un ücretlendirmesi Solid Biosciences'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Mar 31 2026n/an/a

-US$192m

Dec 31 2025US$5mUS$651k

-US$174m

Sep 30 2025n/an/a

-US$167m

Jun 30 2025n/an/a

-US$154m

Mar 31 2025n/an/a

-US$140m

Dec 31 2024US$5mUS$608k

-US$125m

Sep 30 2024n/an/a

-US$102m

Jun 30 2024n/an/a

-US$91m

Mar 31 2024n/an/a

-US$90m

Dec 31 2023US$919kUS$585k

-US$96m

Sep 30 2023n/an/a

-US$91m

Jun 30 2023n/an/a

-US$90m

Mar 31 2023n/an/a

-US$91m

Dec 31 2022US$4mUS$46k

-US$86m

Tazminat ve Piyasa: Bo 'nin toplam tazminatı ($USD 5.22M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 3.73M ).

Tazminat ve Kazançlar: Bo şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Bo Cumbo (54 yo)

3.4yrs
Görev süresi
US$5,223,442
Tazminat

Mr. Alexander G. Cumbo, also known as Bo, has been Independent Director at Vor Biopharma Inc. since July 16, 2025. He is an Independent Director of Climb Bio, Inc. from March 2025. He serves as President,...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Ian Smith
Executive Chair6.1yrsUS$522.68k0.14%
$ 877.0k
Alexander Cumbo
President3.4yrsUS$5.22m0.24%
$ 1.5m
Ilan Ganot
Co-founder13.3yrsUS$337.69k0.15%
$ 951.6k
David Howton
COO & Secretary3.4yrsUS$2.59m0.11%
$ 684.0k
Gabriel Brooks
Chief Medical Officer2.6yrsUS$2.33m0.091%
$ 582.4k
Annie Ganot
Co-Founder & VP of Patient Advocacyno dataVeri yokVeri yok
Kevin Tan
CFO & Treasurer3.3yrsUS$1.36m0.10%
$ 647.3k
Paul Herzich
Chief Technology Officer3.4yrsVeri yok0.074%
$ 472.9k
Nicole Anderson
Senior Director of Investor Relations & Corporate Communicationsno dataVeri yokVeri yok
Jessie Hanrahan
Chief Regulatory & Preclinical Operations Officer3.4yrsVeri yok0.075%
$ 483.8k
Shuli Kulak
Head of Corporate Strategy & Business Development2.7yrsVeri yokVeri yok
3.4yrs
Ortalama Görev Süresi
50yo
Ortalama Yaş

Deneyimli Yönetim: SLDB 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.4 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Ian Smith
Executive Chair6.1yrsUS$522.68k0.14%
$ 877.0k
Alexander Cumbo
President3.4yrsUS$5.22m0.24%
$ 1.5m
Ilan Ganot
Co-founder13.3yrsUS$337.69k0.15%
$ 951.6k
Jeffrey Bluestone
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Laurence Turka
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Jeffrey Chamberlain
Chairman of Scientific Advisory Board8.3yrsVeri yokVeri yok
Adam Stone
Lead Independent Director10.5yrsUS$355.68k0%
$ 0
Lynne Sullivan
Independent Director10.5yrsUS$360.01k0%
$ 0
Carrie Miceli
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Ronald Cohn
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Dongsheng Duan
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Georgia Keresty
Independent Director5.2yrsUS$357.68k0%
$ 0
8.3yrs
Ortalama Görev Süresi
59yo
Ortalama Yaş

Deneyimli Yönetim Kurulu: SLDB 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.3 yıldır).

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/05/19 13:27
Gün Sonu Hisse Fiyatı2026/05/19 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Solid Biosciences Inc. 22 Bu analistlerden 14, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Timothy ChiangBTIG
Kristen KluskaCantor Fitzgerald & Co.
Charles DuncanCantor Fitzgerald & Co.